SUPN Stock: Price, Earnings History and SEC Filings
Supernus Pharmaceuticals, Inc. (SUPN) last traded at $41.92, up 0.19% on the latest session and down 2.6% over the past month. In its most recent reported quarter (Sep 2026) earnings per share were $0.78 against an analyst estimate of $0.34, a beat of 129.4%.
$41.92 +0.19%
1 month-2.60%
52-week high$59.68
52-week low$37.54
Volume2.82M
ExchangeNasdaqGM
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
SUPN earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Sep 2026 | Oct 29, 2026 | $0.78 | $0.34 | +129.41% |
| Jun 2026 | Aug 3, 2026 | $0.39 | $0.30 | +30.00% |
| Mar 2026 | May 5, 2026 | $0.45 | $0.14 | +221.43% |
| Dec 2025 | Feb 24, 2026 | $0.75 | $0.14 | +435.71% |
SUPN beat the analyst EPS estimate in 4 of its last 4 reported quarters. Source: Nasdaq.
SUPN financial history
Revenue
Net income
Free cash flow
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $719M | -$39M | $46M | -5.4% | $-0.68 |
| 2024 | $662M | $74M | $171M | 11.2% | $1.32 |
| 2023 | $608M | $1M | $111M | 0.2% | $0.02 |
| 2022 | $667M | $61M | $116M | 9.1% | $1.04 |
| 2021 | $580M | $53M | – | 9.2% | $0.98 |
| 2020 | $520M | $127M | $135M | 24.4% | $2.36 |
| 2019 | $393M | $113M | $140M | 28.8% | $2.10 |
| 2018 | $409M | $111M | $128M | 27.1% | $2.05 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for SUPN
SEC filing data is not available right now. You can search for SUPN on SEC EDGAR.
SUPN news
- SUPN Q3 deep dive: robust portfolio growth and integration priorities amid Indivior mergerNov 1, 2026 · finance.yahoo.com
- Indivior Pharmaceuticals (INDV) Could Be 30% Undervalued On Its Turnaround NarrativeOct 30, 2026 · finance.yahoo.com
- Supernus (SUPN) Q3 2026 Earnings Call TranscriptOct 30, 2026 · fool.com
- Supernus Pharmaceuticals, Inc. Q3 2026 Earnings Call SummaryOct 30, 2026 · app.moby.co
- Indivior Pharmaceuticals (INDV) Shareholders Back Merger After Record Third QuarterOct 30, 2026 · finance.yahoo.com
- Supernus Pharmaceuticals Q3 Earnings Call HighlightsOct 29, 2026 · marketbeat.com
- Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue EstimatesOct 29, 2026 · finance.yahoo.com
- Supernus: Q3 Earnings SnapshotOct 29, 2026 · finance.yahoo.com
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. (SUPN) is a US-listed public company on Nasdaq.